Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
| 49.33 | |
| 49.33 | |
| - | |
| 49.33 | |
| 49.33 | |
| 41.9239-54.5729 | |
| 5 436 M | |
| 28.8235 | |
| 111 M | |
| 2 875 M | |
| 0.5345 | |
| 0.0294 | |
| 0.397 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
It is hard to get excited after looking at Hikma Pharmaceuticals' (LON:HIK) recent performance, when its stock has declined 6.9% over the past month. It seems that the market might have completely ign...
Key Insights Using the 2 Stage Free Cash Flow to Equity, Hikma Pharmaceuticals fair value estimate is UK£29.89 Hikma Pharmaceuticals is estimated to be 35% undervalued based on current share price o...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
